Bolin Chen
Impact in
-
- Cancer Immunotherapy and Biomarkers
- Inflammatory Biomarkers in Disease Prognosis
- Pathology and Forensic Medicine top 10%
- Spine and Intervertebral Disc Pathology
Papers in
- Oncology 8
- Cancer Immunotherapy and Biomarkers 6
-
- Retinal Diseases and Treatments 4
- Co-authors
- Shing‐Hwa Liu (2 shared papers)Liting Wang (2 shared papers)Chih‐Kang Chiang (2 shared papers)Kuo‐How Huang (2 shared papers)Ching‐Chia Wang (1 shared paper)Fang Xu (6 shared papers)Cheng‐Tien Wu (1 shared paper)Lin Wu (8 shared papers)
In The Last Decade
Bolin Chen
40 papers receiving 701 citations
Bolin Chen's Hit Papers
Peers
Comparison fields: 5 of 64
- Oncology 159
- Pathology and Forensic Medicine 101
- Nephrology 48
- Cancer Research 50
- Pulmonary and Respiratory Medicine 110
Countries citing papers authored by Bolin Chen
This map shows the geographic impact of Bolin Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bolin Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bolin Chen more than expected).
Fields of papers citing papers by Bolin Chen
This network shows the impact of papers produced by Bolin Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bolin Chen. The network helps show where Bolin Chen may publish in the future.
Co-authors
The 25 scholars most cited alongside Bolin Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China Hit paper breakdown → | 2025 | 88 |
| 2 | 2014 | 77 | |
| 3 | 2022 | 69 | |
| 4 | 2013 | 59 | |
| 5 | 2020 | 39 | |
| 6 | 2012 | 35 | |
| 7 | 2023 | 27 | |
| 8 | 2020 | 26 | |
| 9 | 2022 | 26 | |
| 10 | 2023 | 26 | |
| 11 | 2017 | 21 | |
| 12 | 2020 | 20 | |
| 13 | 2022 | 20 | |
| 14 | 2021 | 15 | |
| 15 | 2021 | 12 | |
| 16 | 2022 | 11 | |
| 17 | 2022 | 11 | |
| 18 | 2021 | 10 | |
| 19 | 2023 | 10 | |
| 20 | 2024 | 10 |
About Bolin Chen
Bolin Chen is a scholar working on Oncology, Ophthalmology, Pulmonary and Respiratory Medicine, Cancer Research and Complementary and alternative medicine, having authored 44 papers that have together received 714 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (6 papers), Cancer Immunotherapy and Biomarkers (6 papers), Retinal Diseases and Treatments (4 papers), Acupuncture Treatment Research Studies (3 papers), Acute Kidney Injury Research (2 papers), Spine and Intervertebral Disc Pathology (2 papers), Autophagy in Disease and Therapy (2 papers) and Cancer Genomics and Diagnostics (2 papers). The work is most often cited by research in Oncology (159 citations), Pathology and Forensic Medicine (101 citations), Nephrology (48 citations), Cancer Research (50 citations) and Pulmonary and Respiratory Medicine (110 citations). Bolin Chen has collaborated with scholars based in China, Taiwan and Germany. Frequent co-authors include Shing‐Hwa Liu, Liting Wang, Chih‐Kang Chiang, Kuo‐How Huang, Ching‐Chia Wang, Fang Xu, Cheng‐Tien Wu, Lin Wu, Xuenong Zou and Zemin Ling. Their work appears in journals such as Frontiers in Oncology, BMC Cancer, BMC Pulmonary Medicine, Lung Cancer and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.